Selected research
Market Structure
Global Felodipine Extended-Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Felodipine Extended-Release Tablets market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Felodipine Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Felodipine Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Felodipine Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Felodipine Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Felodipine Extended-Release Tablets include By-Health, CSPC, Zhejiang Cheng Yi Pharmaceutical, Watsons, Schiff, Pfizer, Movefree, KAL and Doppelherz, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Felodipine Extended-Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Felodipine Extended-Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Felodipine Extended-Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Felodipine Extended-Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.
Felodipine Extended-Release Tablets Segment by Company
By-Health
CSPC
Zhejiang Cheng Yi Pharmaceutical
Watsons
Schiff
Pfizer
Movefree
KAL
Doppelherz
Blackmores
AdvaCare
Felodipine Extended-Release Tablets Segment by Type
Tablets
Capsules
Felodipine Extended-Release Tablets Segment by Application
Hospital
Clinic
Pharmacy
Felodipine Extended-Release Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Felodipine Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Felodipine Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Felodipine Extended-Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Felodipine Extended-Release Tablets market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Felodipine Extended-Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Felodipine Extended-Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Felodipine Extended-Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Capsules
Applications
- Hospital
- Clinic
- Pharmacy
Companies covered
- By-Health
- CSPC
- Zhejiang Cheng Yi Pharmaceutical
- Watsons
- Schiff
- Pfizer
- Movefree
- KAL
- Doppelherz
- Blackmores
- AdvaCare
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Felodipine Extended-Release Tablets Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Felodipine Extended-Release Tablets Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Felodipine Extended-Release Tablets Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Felodipine Extended-Release Tablets Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Felodipine Extended-Release Tablets Market Dynamics
- 2.1 Felodipine Extended-Release Tablets Industry Trends
- 2.2 Felodipine Extended-Release Tablets Industry Drivers
- 2.3 Felodipine Extended-Release Tablets Industry Opportunities and Challenges
- 2.4 Felodipine Extended-Release Tablets Industry Restraints
3 Felodipine Extended-Release Tablets Market by Manufacturers
- 3.1 Global Felodipine Extended-Release Tablets Revenue by Manufacturers (2021-2026)
- 3.2 Global Felodipine Extended-Release Tablets Sales by Manufacturers (2021-2026)
- 3.3 Global Felodipine Extended-Release Tablets Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Felodipine Extended-Release Tablets Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Felodipine Extended-Release Tablets Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Felodipine Extended-Release Tablets Manufacturers, Product Type & Application
- 3.7 Global Felodipine Extended-Release Tablets Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Felodipine Extended-Release Tablets Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Felodipine Extended-Release Tablets Players Market Share by Revenue in 2025
- 3.8.3 2025 Felodipine Extended-Release Tablets Tier 1, Tier 2, and Tier 3
4 Felodipine Extended-Release Tablets Market by Type
- 4.1 Felodipine Extended-Release Tablets Type Introduction
- 4.1.1 Tablets
- 4.1.2 Capsules
- 4.2 Global Felodipine Extended-Release Tablets Sales by Type
- 4.2.1 Global Felodipine Extended-Release Tablets Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Felodipine Extended-Release Tablets Sales by Type (2021-2032)
- 4.2.3 Global Felodipine Extended-Release Tablets Sales Market Share by Type (2021-2032)
- 4.3 Global Felodipine Extended-Release Tablets Revenue by Type
- 4.3.1 Global Felodipine Extended-Release Tablets Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Felodipine Extended-Release Tablets Revenue by Type (2021-2032)
- 4.3.3 Global Felodipine Extended-Release Tablets Revenue Market Share by Type (2021-2032)
5 Felodipine Extended-Release Tablets Market by Application
- 5.1 Felodipine Extended-Release Tablets Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Pharmacy
- 5.2 Global Felodipine Extended-Release Tablets Sales by Application
- 5.2.1 Global Felodipine Extended-Release Tablets Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Felodipine Extended-Release Tablets Sales by Application (2021-2032)
- 5.2.3 Global Felodipine Extended-Release Tablets Sales Market Share by Application (2021-2032)
- 5.3 Global Felodipine Extended-Release Tablets Revenue by Application
- 5.3.1 Global Felodipine Extended-Release Tablets Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Felodipine Extended-Release Tablets Revenue by Application (2021-2032)
- 5.3.3 Global Felodipine Extended-Release Tablets Revenue Market Share by Application (2021-2032)
6 Global Felodipine Extended-Release Tablets Sales by Region
- 6.1 Global Felodipine Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Felodipine Extended-Release Tablets Sales by Region (2021-2032)
- 6.2.1 Global Felodipine Extended-Release Tablets Sales by Region (2021-2026)
- 6.2.2 Global Felodipine Extended-Release Tablets Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Felodipine Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Felodipine Extended-Release Tablets Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Felodipine Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Felodipine Extended-Release Tablets Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Felodipine Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Felodipine Extended-Release Tablets Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Felodipine Extended-Release Tablets Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Felodipine Extended-Release Tablets Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Felodipine Extended-Release Tablets Revenue by Region
- 7.1 Global Felodipine Extended-Release Tablets Revenue by Region
- 7.1.1 Global Felodipine Extended-Release Tablets Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Felodipine Extended-Release Tablets Revenue by Region (2021-2026)
- 7.1.3 Global Felodipine Extended-Release Tablets Revenue by Region (2027-2032)
- 7.1.4 Global Felodipine Extended-Release Tablets Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Felodipine Extended-Release Tablets Revenue (2021-2032)
- 7.2.2 North America Felodipine Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Felodipine Extended-Release Tablets Revenue (2021-2032)
- 7.3.2 Europe Felodipine Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Felodipine Extended-Release Tablets Revenue (2021-2032)
- 7.4.2 Asia-Pacific Felodipine Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Felodipine Extended-Release Tablets Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Felodipine Extended-Release Tablets Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 By-Health
- 8.1.1 By-Health Company Information
- 8.1.2 By-Health Business Overview
- 8.1.3 By-Health Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 By-Health Felodipine Extended-Release Tablets Product Portfolio
- 8.1.5 By-Health Recent Developments
- 8.2 CSPC
- 8.2.1 CSPC Company Information
- 8.2.2 CSPC Business Overview
- 8.2.3 CSPC Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 CSPC Felodipine Extended-Release Tablets Product Portfolio
- 8.2.5 CSPC Recent Developments
- 8.3 Zhejiang Cheng Yi Pharmaceutical
- 8.3.1 Zhejiang Cheng Yi Pharmaceutical Company Information
- 8.3.2 Zhejiang Cheng Yi Pharmaceutical Business Overview
- 8.3.3 Zhejiang Cheng Yi Pharmaceutical Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Zhejiang Cheng Yi Pharmaceutical Felodipine Extended-Release Tablets Product Portfolio
- 8.3.5 Zhejiang Cheng Yi Pharmaceutical Recent Developments
- 8.4 Watsons
- 8.4.1 Watsons Company Information
- 8.4.2 Watsons Business Overview
- 8.4.3 Watsons Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Watsons Felodipine Extended-Release Tablets Product Portfolio
- 8.4.5 Watsons Recent Developments
- 8.5 Schiff
- 8.5.1 Schiff Company Information
- 8.5.2 Schiff Business Overview
- 8.5.3 Schiff Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Schiff Felodipine Extended-Release Tablets Product Portfolio
- 8.5.5 Schiff Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Felodipine Extended-Release Tablets Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Movefree
- 8.7.1 Movefree Company Information
- 8.7.2 Movefree Business Overview
- 8.7.3 Movefree Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Movefree Felodipine Extended-Release Tablets Product Portfolio
- 8.7.5 Movefree Recent Developments
- 8.8 KAL
- 8.8.1 KAL Company Information
- 8.8.2 KAL Business Overview
- 8.8.3 KAL Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 KAL Felodipine Extended-Release Tablets Product Portfolio
- 8.8.5 KAL Recent Developments
- 8.9 Doppelherz
- 8.9.1 Doppelherz Company Information
- 8.9.2 Doppelherz Business Overview
- 8.9.3 Doppelherz Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Doppelherz Felodipine Extended-Release Tablets Product Portfolio
- 8.9.5 Doppelherz Recent Developments
- 8.10 Blackmores
- 8.10.1 Blackmores Company Information
- 8.10.2 Blackmores Business Overview
- 8.10.3 Blackmores Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Blackmores Felodipine Extended-Release Tablets Product Portfolio
- 8.10.5 Blackmores Recent Developments
- 8.11 AdvaCare
- 8.11.1 AdvaCare Company Information
- 8.11.2 AdvaCare Business Overview
- 8.11.3 AdvaCare Felodipine Extended-Release Tablets Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 AdvaCare Felodipine Extended-Release Tablets Product Portfolio
- 8.11.5 AdvaCare Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Felodipine Extended-Release Tablets Value Chain Analysis
- 9.1.1 Felodipine Extended-Release Tablets Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Felodipine Extended-Release Tablets Production Mode & Process
- 9.2 Felodipine Extended-Release Tablets Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Felodipine Extended-Release Tablets Distributors
- 9.2.3 Felodipine Extended-Release Tablets Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst